Liquid biopsy firm Nucleix said that its methylation-based Bladder EpiCheck urine test produced strong results for detecting high-risk, non-muscle invasive bladder cancer (NMIBC) in a study published online June 11 in the Journal of Clinical Pathology.
In a study of 374 patients at Agostino Gemelli University Hospital in Rome, Italy, the firm's methylation-based assay outperformed cytology alone and yielded high sensitivity, specificity, and negative predictive value, Nucleix said. The findings support the use of Bladder EpiCheck to detect recurrence of NMIBC in patients who have undergone instillations, according to the vendor.
